A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes

Area of Science:

• Genomics
• Systems Biology
• Pharmacology

Background:

• Drug resistance is a major challenge in cancer chemotherapy.
• Understanding and manipulating drug response phenotypes is crucial for effective treatment.

Purpose of the Study:

• To develop a network-based approach (P-Map) for identifying gene candidates that can alter drug sensitivity.
• To explore the possibility of manipulating drug response phenotypes in cancer cells.
• To identify potential targets for overcoming drug resistance.

Main Methods:

• Utilized basal transcriptomics data from human lymphoblastoid cell lines (LCL).
• Inferred drug response networks (DRNs) for anthracycline and taxane response phenotypes.
• Tested selected gene candidates interacting with phenotypic differentially expressed genes (PDEGs) in triple-negative breast cancer (TNBC) cells.

Main Results:

• Demonstrated that perturbing gene candidates in DRNs can alter drug response phenotypes (resistant to sensitive, or vice versa).
• Identified plausible mechanisms regulating the directionality of drug response sensitivity.
• Validated the approach in TNBC cells.

Conclusions:

• The P-Map approach offers a novel strategy for identifying genes that modulate cancer drug sensitivity.
• Perturbing identified gene candidates can potentially reverse drug resistance phenotypes.
• This work highlights a new direction for systems-based therapeutic design, focusing on phenotypic modulators to re-sensitize resistant cancers.